Theravance Biopharma, Inc. (TBPH) is an innovative biopharmaceutical company dedicated to developing organ-selective therapeutics that address critical unmet medical needs, particularly in respiratory diseases. Utilizing its proprietary technologies and extensive scientific expertise, the company aims to create transformative therapies that significantly enhance patient outcomes. Headquartered in George Town, Cayman Islands, with a global presence across the United States, Europe, and Asia, Theravance is strategically positioned to capitalize on growth opportunities in the dynamic biopharmaceutical sector. Show more

Location: 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, South San Francisco, CA, 94080, USA | Website: https://www.theravance.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

959.7M

52 Wk Range

$7.90 - $21.03

Previous Close

$18.94

Open

$19.12

Volume

306,511

Day Range

$18.98 - $20.02

Enterprise Value

674.7M

Cash

174.8M

Avg Qtr Burn

-6.508M

Insider Ownership

4.07%

Institutional Own.

98.08%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
YUPELRI® (revefenacin) Details Chronic obstructive pulmonary disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRELEGY ELLIPTA Details Asthma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRELEGY ELLIPTA Details Chronic obstructive pulmonary disease (COPD)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ampreloxetine (TD-9855) Details Multiple System Atrophy, Neurogenic orthostatic hypotension	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nezulcitinib (TD-0903) (Janus kinase inhibitor (JAKi)) Details COVID-19, Skin disease/disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Inflammatory bowel disease, Inflammatory disease, Ulcerative colitis, Crohns disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Crohns disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.